ASN
SCNI

Advisory Services Network’s Scinai Immunotherapeutics SCNI Stock Holding History

Advisory Services Network’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-51
Closed -$14K – 2910
2021
Q2 		$14K Buy
+51
New +$15.9K ﹤0.01% 2658

Other funds holding SCNI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisory Services Network's SCNI Position: Q3 2021 in Review

Advisory Services Network sold out of Scinai Immunotherapeutics (SCNI) in Q3 2021, closing a stake of 51 shares — an estimated $14K sold.

Advisory Services Network first reported a position in SCNI in Q2 2021 and held it in 1 quarter. The position peaked at $14K in Q2 2021. 17 funds tracked by Wall St. Rank hold SCNI as of Q3 2021.

  • Advisory Services Network reported no remaining Scinai Immunotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Advisory Services Network sold 51 Scinai Immunotherapeutics shares in Q3 2021, an estimated $14K.
  • Advisory Services Network first reported a position in Scinai Immunotherapeutics in Q2 2021 and held it in 1 quarter.
  • Advisory Services Network's Scinai Immunotherapeutics position peaked at $14K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2021.

Based on Advisory Services Network's 13F filing for Q3 2021, filed 5 Nov 2021.